Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease
-
Narrado por:
-
De:
Acerca de esta escucha
In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:
- The available biologic therapies that specifically target IL-13
- Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm
- How these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitors
- A detailed patient case to highlight take home points
Presenter
Andrew F. Alexis, MD, MPH
Professor of Clinical Dermatology
Weill Cornell Medical College
New York, New York
Daniel C. Butler, MD
Assistant Dean Student Affairs
University of Arizona College of Medicine – Tucson
Tucson, Arizona
Shawn G. Kwatra, MD
Dr. Joseph W. Burnett Endowed Professor and Chair
Department of Dermatology
University of Maryland School of Medicine
Baltimore, Maryland
Program page:
https://bit.ly/4kTP04D
Todavía no hay opiniones